SAGE announces the launch of "Therapeutic Advances in Musculoskeletal Disease"

First issue out now

SAGE has announced the launch of Therapeutic Advances in Musculoskeletal Disease, the latest in SAGE's highly-regarded Therapeutic Advances series.

Therapeutic Advances in Musculoskeletal Disease is for all professionals concerned with research into, and the practice of, musculoskeletal disease and is a forum for all views on related subjects. The journal offers rapid peer review and publication, with manuscripts published online within 7 weeks of acceptance.

The editors welcome original research and review articles of latest advances in the treatment of arthropathies and other joint disorders, systemic connective tissue disorders, dorsopathies, soft tissue disorders, osteopathies and chondropathies.

Editor in Chief, Philip Sambrook OAM, has published over 270 peer reviewed papers including invited editorials in the New England Journal of Medicine, British Medical Journal and The Lancet. In addition he is the current President of the Australian & New Zealand Bone & Mineral Society, on the Committee of Scientific Advisors of The International Osteoporosis Foundation, and on the Board of the International Bone and Mineral Society.

"Musculoskeletal disease is affecting an increasing proportion of our ageing population - the chronic diseases it includes have led to many new categories of medical treatments that are changing the way we manage patients," said Philip Sambrook. "While there are many journals in this growing area, my feeling is that we still need to have more avenues to publish and access the material. For this reason, I am enthusiastic about leading the launch of this new journal."

Therapeutic Advances in Musculoskeletal Disease is the seventh journal to be launched within the Therapeutic Advances series. Each journal publishes six issues per year and will be freely available on the award-winning SAGE Journals Online platform for the first three years of publication.

"We're delighted to be working with such a distinguished Editor in Chief and editorial board to continue the successful growth of the Therapeutic Advances series," said Tessa Picknett, Publisher, STM journals. "Launching new journals continues to become more challenging, but the impact that this series has made indicates there is still demand for access to timely peer reviewed content across therapeutic treatments."